<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="HA5D80D42057343A8BBFF104876F45D37" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>118 HR 1458 IH: Access to Prescription Digital Therapeutics Act of 2023</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2023-03-08</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">118th CONGRESS</congress><session display="yes">1st Session</session><legis-num display="yes">H. R. 1458</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20230308">March 8, 2023</action-date><action-desc><sponsor name-id="H001082">Mr. Hern</sponsor> (for himself, <cosponsor name-id="T000460">Mr. Thompson of California</cosponsor>, <cosponsor name-id="J000292">Mr. Johnson of Ohio</cosponsor>, and <cosponsor name-id="M001163">Ms. Matsui</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name>, and in addition to the Committee on <committee-name committee-id="HWM00">Ways and Means</committee-name>, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned</action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To amend titles XVIII and XIX of the Social Security Act to provide for coverage of prescription digital therapeutics under such titles, and for other purposes.</official-title></form><legis-body id="H8604E2740683492895E594B3CA4D42F5" style="OLC"><section id="H2F38AE8C794F421DA76387CE18C0CC42" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Access to Prescription Digital Therapeutics Act of 2023</short-title></quote>.</text></section><section id="HCF9BE0DA99F4410CBAE243AC965232D4"><enum>2.</enum><header>Coverage and payment of prescription digital therapeutics under the Medicare program</header><subsection id="H7EB8C134ED474765B2FA5412E232E622"><enum>(a)</enum><header>Prescription digital therapeutic defined</header><text>Section 1861 of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395x">42 U.S.C. 1395x</external-xref>) is amended by adding at the end the following new subsection:</text><quoted-block style="OLC" id="HEAFF3037E83046A3B3F2F37C60E0A22F" display-inline="no-display-inline"><subsection id="H29553142795F43759AED1D9AB5BF1AE1"><enum>(nnn)</enum><header>Prescription digital therapeutic</header><text>The term <term>prescription digital therapeutic</term> means a product, device, internet application, or other technology that—</text><paragraph id="H6AEE468D0AB3485AB95B460D2A260FD8"><enum>(1)</enum><text display-inline="yes-display-inline">is cleared or approved under section 510(k), 513(f)(2), or 515 of the Federal Food, Drug, and Cosmetic Act;</text></paragraph><paragraph id="H50B43C99104B43DF895AB4E9CE743AC5"><enum>(2)</enum><text>has a cleared or approved indication for the prevention, management, or treatment of a medical disease, condition, or disorder;</text></paragraph><paragraph id="H1DBC1F3AD1FC4FBD926345EFF36D6EE2"><enum>(3)</enum><text>primarily uses software to achieve its intended result; and</text></paragraph><paragraph id="HA1096D0B09234B008C4D678C3F5F9A39" commented="no"><enum>(4)</enum><text display-inline="yes-display-inline">is a device that is exempt from section 502(f)(1) of the Federal Food, Drug, and Cosmetic Act under section 801.109 of title 21 of the Code of Federal Regulations (or any successor regulation).</text></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block></subsection><subsection id="H5A3F0EE0E02846899C5489AB55DEE3FF"><enum>(b)</enum><header>Coverage as medical and other health service</header><text>Section 1861(s)(2) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395x">42 U.S.C. 1395x(s)(2)</external-xref>) is amended—</text><paragraph id="H7315B0A2D37A4AC2B412C941271B82BC"><enum>(1)</enum><text>in subparagraph (HH), by striking <quote>and</quote> at the end;</text></paragraph><paragraph id="H22720B6E5C534CC7AD21A8FBE9BBAA30"><enum>(2)</enum><text>in subparagraph (II), by striking the period at the end and inserting <quote>; and</quote>; and</text></paragraph><paragraph id="H33D7921911284E32AAD50ADE285CD3FF"><enum>(3)</enum><text>by adding at the end the following new subparagraph:</text><quoted-block style="OLC" id="HDBE3318DDAAC438F8A6470E400972840" display-inline="no-display-inline"><subparagraph id="HD8A288621EC846A08A0F43E5DFE4BF0D"><enum>(JJ)</enum><text display-inline="yes-display-inline">prescription digital therapeutics (as defined in subsection (nnn)) furnished on or after January 1, 2024;</text></subparagraph><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></subsection><subsection id="HBA93D645A11E4AD58E3F66C72A5E8B89"><enum>(c)</enum><header>Requirements for prescription digital therapeutics under Medicare</header><text>Part B of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395j">42 U.S.C. 1395j et seq.</external-xref>) is amended by inserting after section 1834A the following new section:</text><quoted-block style="OLC" id="H4C7A1630CEC2455BB183B49FC7A8EB72" display-inline="no-display-inline"><section id="H1CE9201D7DF24EB78060599BD767B1EF"><enum>1834B.</enum><header>Requirements for prescription digital therapeutics</header><subsection id="H3E310C21A87246EF972CF124CE63500B"><enum>(a)</enum><header>Payment</header><paragraph id="H00B3416133554673A71260D6F1A3B371" commented="no"><enum>(1)</enum><header>In general</header><text display-inline="yes-display-inline">Not later than 1 year after the date of enactment of this section, the Secretary shall establish a payment methodology for manufacturers of prescription digital therapeutics, which may consist of a one-time payment or periodic payments, as determined appropriate by the Secretary.</text></paragraph><paragraph id="H2F1F022EAF544D69B70D1B0D8A278D20"><enum>(2)</enum><header>Considerations for payment methodology</header><text display-inline="yes-display-inline">For purposes of establishing the payment methodology under paragraph (1), the Secretary shall consider—</text><subparagraph id="H90A88CEA7284466CA96C77F60BA75BAE"><enum>(A)</enum><text>the actual list charge of such prescription digital therapeutic;</text></subparagraph><subparagraph id="H5901FD7DFC724C5594F5562F27726496"><enum>(B)</enum><text display-inline="yes-display-inline">the weighted median (calculated by arraying the distribution of all payment rates reported for the most recent period for which such rates were reported under subsection (c)(1) for each prescription digital therapeutic weighted by volume for each payor and each manufacturer) for such prescription digital therapeutic;</text></subparagraph><subparagraph id="HC85A6C07E87B4594B03C583006DB5749"><enum>(C)</enum><text display-inline="yes-display-inline">in the case of a prescription digital therapeutic that requires ongoing use, the amount for such ongoing use; and</text></subparagraph><subparagraph id="HB46BAC22B9944A3A9BB21349580169B6"><enum>(D)</enum><text>other factors as determined by the Secretary.</text></subparagraph></paragraph></subsection><subsection id="H065894E05215416B8224A5B3C485BE66"><enum>(b)</enum><header>Coding</header><paragraph id="HA64AAD4839FA484BB8C0C5C1CE5D6EE6"><enum>(1)</enum><header>In general</header><text>Not later than 2 years after the date of enactment of this section, the Secretary shall establish product-specific HCPCS codes for prescription digital therapeutic covered under this title.</text></paragraph><paragraph id="H61AD1434F1FB415B8CDCC8A0CF9A2212"><enum>(2)</enum><header>Temporary code</header><text>The Secretary shall adopt temporary product-specific HCPCS codes for purposes of providing payment under this title until a permanent product-specific HCPCS code has been established under paragraph (1).</text></paragraph></subsection><subsection id="H23E938C483134FE298AA2A7DEF7DD824"><enum>(c)</enum><header>Manufacturer reporting</header><paragraph id="HA7264B12580B45D59BE655B20CF66886"><enum>(1)</enum><header>In general</header><text>Beginning on January 1, 2024, each manufacturer of a prescription digital therapeutic covered under this title shall submit to the Secretary, at such time and in such manner as specified by the Secretary, and annually thereafter, a report describing—</text><subparagraph id="HB7416D1FC6C64936A23476346EF6B5C6"><enum>(A)</enum><text>the payment rate that was paid by each private payor for each prescription digital therapeutic during the period specified by the Secretary;</text></subparagraph><subparagraph id="H83949DF888E54D5AA23BE4CAB51A0E86"><enum>(B)</enum><text display-inline="yes-display-inline">the volume of such prescription digital therapeutic distributed to each such payor for such period; and</text></subparagraph><subparagraph id="H28125852BC68460CACFB2BBE9E7AAC4B"><enum>(C)</enum><text>the number of individual users of such prescription digital therapeutic for such period.</text></subparagraph></paragraph><paragraph id="HF9CB1E60B5584721B73E54D1703F5A9F"><enum>(2)</enum><header>Treatment of discounts</header><text display-inline="yes-display-inline">The payment rate reported by a manufacturer in accordance with paragraph (1)(A) shall reflect all discounts, rebates, coupons, and other price concessions, including those described in section 1847A(c)(3).</text></paragraph><paragraph id="HD542CCD280ED4278961A45FD1C11A352"><enum>(3)</enum><header>Civil monetary penalty</header><subparagraph id="H4BAD3ACED53C41E78A5C4BBE2CBE7CE8"><enum>(A)</enum><header>In general</header><text>If the Secretary determines that a manufacturer has failed to report, or made a misrepresentation or omission in reporting, information under this subsection with respect to a prescription digital therapeutic, the Secretary may apply a civil money penalty in an amount of up to $10,000 per day for each failure to report or each such misrepresentation or omission.</text></subparagraph><subparagraph id="H9ACF80FEEEAF45CA9BAF9986B9CA694A"><enum>(B)</enum><header>Application</header><text>The provisions of section 1128A (other than subsections (a) and (b)) shall apply to a civil money penalty under this paragraph in the same manner as they apply to a civil money penalty or proceeding under section 1128A(a).</text></subparagraph></paragraph><paragraph id="HCDC8C2E1122C4DF3A1FA2AFA22F03A5D"><enum>(4)</enum><header>Confidentiality</header><text>Information reported under this subsection shall be treated in the same manner in which information is disclosed by a manufacturer or a wholesaler of a covered outpatient is treated under section 1927(b)(3)(D).</text></paragraph></subsection><subsection id="HD1CA46EFD0634C199FF3146487AFD915"><enum>(d)</enum><header>Definitions</header><text>For purposes of this section:</text><paragraph id="H181F50F43EB4457DA2BEC2B3231A9959"><enum>(1)</enum><header>Actual list charge</header><text>The term <quote>actual list charge</quote> means the publicly available payment rate for a prescription digital therapeutic on the first day that such prescription digital therapeutic is available for purchase by a private payor. </text></paragraph><paragraph id="HFEAC601932E2485AA3291220D8DE7AC0"><enum>(2)</enum><header>HCPCS</header><text display-inline="yes-display-inline">The term <term>HCPCS</term> means, with respect to an item, the code under the Healthcare Common Procedure Coding System (HCPCS) (or a successor code) for such item.</text></paragraph><paragraph id="H7B70376BB73F4B939550958CC26752FE"><enum>(3)</enum><header>Manufacturer</header><text>The term <term>manufacturer</term> has the meaning given such term by section 820.3(o) of title 21, Code of Federal Regulations (or any successor regulation).</text></paragraph><paragraph id="H1C176E4FAE1A4196924710F63D34619D"><enum>(4)</enum><header>Prescription digital therapeutic</header><text>The term <quote>prescription digital therapeutic</quote> has the meaning given such term in section 1861(nnn). </text></paragraph><paragraph id="H975868D15DC4486B9CA85A321EF4FEF1"><enum>(5)</enum><header>Private payor</header><text>The term <quote>private payor</quote> has the meaning given such term in section 1834A(a)(8).</text></paragraph></subsection></section><after-quoted-block>.</after-quoted-block></quoted-block></subsection></section><section id="H46ACB9DC56A4438AA29C0079A0200204"><enum>3.</enum><header>Coverage of prescription digital therapeutics under the Medicaid program</header><text display-inline="no-display-inline">Section 1905(a) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1396d">42 U.S.C. 1396d(a)</external-xref>) is amended—</text><paragraph id="HB6583302A92C4936A308AA69C8969059"><enum>(1)</enum><text>in paragraph (30), by striking <quote>; and</quote> and inserting a semicolon;</text></paragraph><paragraph id="H78CB84F55C0D48BAA78708ED67643D0C"><enum>(2)</enum><text>by redesignating paragraph (31) as paragraph (32); and</text></paragraph><paragraph id="HDA8FF114E8E04178A224C6ECE400C648"><enum>(3)</enum><text>by inserting the following paragraph after paragraph (30):</text><quoted-block id="H8D7DCD79F22847BCBD589EA5793A87DF" style="OLC"><paragraph id="H35FB42BF1C3A4B9BA896671912190203"><enum>(31)</enum><text>prescription digital therapeutics (as defined in section 1861(nnn)); and</text></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></section></legis-body></bill> 

